Zevra Therapeutics (ZVRA) Free Cash Flow (2014 - 2026)

Zevra Therapeutics has reported Free Cash Flow for 13 years, with the latest figure at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 173.39% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $12.0 million (up 119.4% YoY), and the FY2025 full-year result was -$2.4 million, up 96.51% from the prior year.
• Free Cash Flow for Q1 2026 stood at $6.1 million, up from $5.5 million in the prior quarter.
• The five-year high for Free Cash Flow was $6.1 million in Q1 2026, with the low at -$19.1 million in Q2 2024.
• Historically, Free Cash Flow has averaged -$7.0 million across 5 years, with a median of -$4.8 million in 2023.
• Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 419.77% — and 2026, when it jumped 173.39%.
• Zevra Therapeutics' Free Cash Flow stood at -$4.5 million in 2022, then tumbled by 260.99% to -$16.2 million in 2023, then declined by 0.12% to -$16.2 million in 2024, then jumped by 134.14% to $5.5 million in 2025, then grew by 10.1% to $6.1 million in 2026.
• The last three Free Cash Flow figures came in at $6.1 million (Q1 2026), $5.5 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.